Acella announced the approval of an Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection 1000mg/10mL, the generic version of Pfizer’s Cyklokapron.

Cyklokapron is a plasminogen activation inhibitor indicated for the short-term use in hemophilia to reduce or prevent hemorrhage, and reduce the need for replacement therapy during and following tooth extraction. Tranexamic acid interferes with the fibrinolytic process in the same way as aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid.

RELATED: Tranexamic Acid Safe for Wide Spectrum of Trauma Patients

Tranexamic Acid Injection will be available in a 1000mg/10mL (100mg/mL) strength.

For more information call (678) 325-5189 or visit